Anti-NT2NA/ NOTCH2NLA/ N2N functional antibody

Anti-NT2NA/ NOTCH2NLA/ N2N functional antibody for cell culture, ELISA & in-vivo assay

Target products collectionGo to NOTCH2NLA/NOTCH2NLA products collection >>
(antibodies, antigen, VLP, mRNA, ORF viral vector, etc)

pdfMSDSpdfCOApdfDatasheet

Product information

Catalog No.Product NameSpecies Reactivity
GM-Tg-hg-SE1129-Ab-1/ GM-Tg-hg-SE1129-Ab-2Anti-Human NOTCH2NLA monoclonal antibodyHuman
GM-Tg-rg-SE1129-Ab-1/ GM-Tg-rg-SE1129-Ab-2Anti-Rat NOTCH2NLA monoclonal antibodyRat
GM-Tg-mg-SE1129-Ab-1/ GM-Tg-mg-SE1129-Ab-2Anti-Mouse NOTCH2NLA monoclonal antibodyMouse
GM-Tg-cynog-SE1129-Ab-1/ GM-Tg-cynog-SE1129-Ab-2Anti-Cynomolgus/ Rhesus macaque NOTCH2NLA monoclonal antibodyCynomolgus/ Rhesus macaque
GM-Tg-felg-SE1129-Ab-1/ GM-Tg-felg-SE1129-Ab-2Anti-Feline NOTCH2NLA monoclonal antibodyFeline
GM-Tg-cang-SE1129-Ab-1/ GM-Tg-cang-SE1129-Ab-2Anti-Canine NOTCH2NLA monoclonal antibodyCanine
GM-Tg-bovg-SE1129-Ab-1/ GM-Tg-bovg-SE1129-Ab-2Anti-Bovine NOTCH2NLA monoclonal antibodyBovine
GM-Tg-equg-SE1129-Ab-1/ GM-Tg-equg-SE1129-Ab-2Anti-Equine NOTCH2NLA monoclonal antibodyEquine

Size： 1mg | 10mg | 100mg



Product Description

Catalog No.GM-Tg-hg-SE1129-Ab-1/ GM-Tg-hg-SE1129-Ab-2; GM-Tg-rg-SE1129-Ab-1/ GM-Tg-rg-SE1129-Ab-2;
GM-Tg-mg-SE1129-Ab-1/ GM-Tg-mg-SE1129-Ab-2; GM-Tg-cynog-SE1129-Ab-1/ GM-Tg-cynog-SE1129-Ab-2;
GM-Tg-felg-SE1129-Ab-1/ GM-Tg-felg-SE1129-Ab-2; GM-Tg-cang-SE1129-Ab-1/ GM-Tg-cang-SE1129-Ab-2;
GM-Tg-bovg-SE1129-Ab-1/ GM-Tg-bovg-SE1129-Ab-2; GM-Tg-equg-SE1129-Ab-1/ GM-Tg-equg-SE1129-Ab-2
Products NameAnti-NOTCH2NLA monoclonal antibody
Formatmab
Target NameNOTCH2NLA
Protein Sub-locationSecreted Protein/Potential Cytokines
Category of antibodyFACS/Biofunctional Antibody
Derivation (species)Mouse
CH1+2+3 Isotype
(Receptor identification)		IgG
Type of Light Chain (VD-LC)N/A
Expression platformMammalian Expression
Bioactivity validationBinding affinity is validated by ELISA with recombinant soluble protein antigen. The biofunction of antibodies are validated with in-vitro assay (IC50 or EC50 TBD).
TagFc
Products descriptionPre-made anti-NOTCH2NLA benchmark inhibitory monoclonal antibody(mab) (blocking antibody inhibitor) is expressed by mammalian cell line as a benchmark antibody for cell culture, ELISA or other affinity binding assay or functional assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic)
Purity Purity: ≥95% (SDS-PAGE)
Application Biological drug disovery including cell culture, assay development, animal model development, PK/PD model development (Pharmacokinetics & Pharmacodynamic) and mechanism of action (MOA) research.
Formulation & Reconstitution Lyophilized from GM's Protein Stability Buffer2 (PSB2,Confidential Ingredients) or PBS (pH7.4);
For PSB2, reconstituted with 0.9% sodium chloride;
For PBS, reconstituted with ddH2O.
Storage Store at -20℃ to -80℃ under sterile conditions. Avoid repeated freeze-thaw cycles.

Reference




    Data / case study


    Click to get more Data / Case study about the product.



    Associated products


    CategoryCat No.Products Name
    Target AntigenGM-Tg-g-SE1129-Ag-1Recombinant multi-species NT2NA/ NOTCH2NLA/ N2N protein


    Target information

    Target IDGM-SE1129
    Target NameNOTCH2NLA
    Gene ID388677
    Gene Symbol and SynonymsN2N,NOTCH2NL,NOTCH2NLA
    Uniprot AccessionQ7Z3S9
    Uniprot Entry NameNT2NA_HUMAN
    Protein Sub-locationSecreted Protein/Potential Cytokines
    Category
    DiseaseN/A
    Gene EnsemblENSG00000264343
    Target ClassificationN/A

    The target: NOTCH2NLA, gene name: NOTCH2NLA, also named as N2N, NOTCH2NL. Enables Notch binding activity. Involved in cerebral cortex development and positive regulation of Notch signaling pathway. Located in extracellular region. [provided by Alliance of Genome Resources, Apr 2022].



    About Gmab

    GDU
    GDU



    GMab, developed by GeneMedi, constitutes an advanced library of recombinant monoclonal antibodies, each meticulously designed to target specific molecular entities. Leveraging the sophisticated capabilities of GM’s Taurus™ and LIBRA™ platforms, GMab synthesizes antibodies characterized by high binding affinity, exceptional physicochemical stability, and optimal developability profiles.

    Through expression in mammalian cell lines, GMab has been established as a paradigmatic reference antibody. It holds significance in myriad domains of biological drug discovery, encompassing cellular cultivation, innovative assay methodologies, strategic animal model systematization, in-depth pharmacokinetic & pharmacodynamic (PK/PD) modeling, and intricate mechanism of action (MOA) investigations.